Novo Nordisk: The Selloff Is A Blessing In Disguise [Seeking Alpha]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Seeking Alpha
NVO faces near-term headwinds from U.S. pricing pressure, patent expirations, and manufacturing ramp-up delays, but underlying free cash flow and profitability remain robust. The Wegovy pill's rapid uptake and first-mover advantage, alongside CagriSema's promising efficacy, position NVO for long-term GLP-1 market leadership. NVO stock valuation is compelling with a GAAP P/E of 12.22, a 4% dividend yield, and a new $2.38B buyback, offering significant upside even under bearish scenarios. hapabapa/iStock Editorial via Getty Images Introduction The start of 2026 started so well for Novo Nordisk A/S ( NVO ) (trading in Denmark as NOVO-B.CO) in terms of share price appreciation, and it quickly turned into a proverbial disaster following the announcement This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of NVO either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own o
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo Nordisk A/S (NYSE:NVO) was upgraded by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from a "sell (d+)" rating to a "hold (c-)" rating.MarketBeat
- TrumpRx: See the 43 drugs available on the Trump administration's new discounted drug site [CBS News]CBS News
- Eli Lilly vs Novo Nordisk: The 1 Figure Investors Shouldn't Ignore [Yahoo! Finance]Yahoo! Finance
- Hims & Hers shares tick lower after Novo's legal threat [MSNBC.com]MSNBC.com
- Many 2026 Super Bowl ads share a common theme, revealing a truth about America's current mindset By Mae Anderson and The Associated Press By Mae Anderson and The Associated Press February 6, 2026, 2:06 PM ET [Fortune]Fortune
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 2/5/26 - Form 6-K
- 2/5/26 - Form 6-K
- 2/5/26 - Form 6-K
- NVO's page on the SEC website